Revolution Medicines responds to questions about Daraxonrasib pricing and access in Canada

If you are just hearing about Daraxonrasib, here is the short version. Daraxonrasib, sold in the United States as Rasonque, is a new pill for pancreatic cancer made by the U.S. company Revolution Medicines. It was approved by the U.S. Food and Drug Administration on August 26, 2026. In Canada, it is not approved, and the company has not applied to Health Canada.

That leaves Canadian patients and families with the same three questions: Can we get it? How? And what will it cost? The Heather Cutler Foundation put those questions to Revolution Medicines directly. This is what the company told us, and what it did not.

For the full picture of where things stand in Canada, read our explainer, Is Daraxonrasib Available in Canada? For what the research found, read Daraxonrasib Just Doubled Survival in Pancreatic Cancer. Here's What That Means for Canadians.

Why we contacted Revolution Medicines

Since the FDA approval, Canadians with pancreatic cancer have been asking the same questions online and getting no clear answers. On Reddit, patients and families are comparing international pharmacies and weighing trips to the United States. There is a real sense of panic in the community.

One of those patients is Salman Syed, an Ontario man with stage IV pancreatic cancer who started the patient-led campaign Pancreatic Cancer Can't Wait. On his site he details how Revolution Medicines said it would not fund the drug or support compassionate access. His oncologist has applied through Health Canada's Special Access Program. We wanted the company to tell us, on the record, whether that is its position for Canadian patients generally. Our email went out to Revolution Medicines on October 31.

A Revolution Medicines spokesperson replied on November 5, 2026. The company named Andrew White, Global Patient Advocacy, as our contact going forward.

What the company said about access outside the United States

Revolution Medicines runs what it calls Global Named Patient Access. This is a way for a doctor to request the drug for one specific patient, in certain countries, before it is approved there. The request has to come from the doctor. The company does not advertise it or reach out to patients. Each request is reviewed against clinical criteria and the rules of the patient's country.

The company told us:

"Submission of a request does not guarantee access, supply or approval."

In plain English: a doctor can ask, but the company can still say no. Even if Health Canada would allow it, the company decides whether to send the drug.

"Daraxonrasib is supplied on a paid basis in accordance with pathway terms and applicable local requirements."

In plain English: this is not a free program. If the company agrees to supply the drug, someone has to pay for it. You may see claims online that the company provides it free to eligible patients. Its statement to us says the opposite for this pathway.

If you or someone you love wants to explore this, the first step is a conversation with your oncologist. Patients cannot apply on their own.

What it confirmed about pricing

The company confirmed its U.S. list price, known as the wholesale acquisition cost:

• US$19,900 per bottle
• US$39,800 for a 30-day supply

At that rate, a year of treatment comes to more than US$475,000 before any insurance or discounts.

What this means for Canadians: this is the U.S. price. The company did not tell us what a Canadian patient would be charged through its access pathway. Please do not treat the U.S. number as the Canadian cost. We simply do not know it yet.

The company also told us its U.S. expanded access program is now closed to new requests, because the drug is approved there. The U.S. patient assistance programs mentioned in its reply do not extend to patients in Canada.

What remains unanswered for Canadians

The company did not answer these questions:

• Will it supply Daraxonrasib through Health Canada's Special Access Program, and on what terms?
• Has it received, or filled, any Special Access Program request from a Canadian doctor?
• What would a Canadian patient be charged?
• Is there any reduced-price or no-cost help for Canadian patients?

The company also declined to discuss individual patient cases, citing privacy. That is reasonable. But the questions above are not about any one person. They are about how the system works for every Canadian family facing this disease.

Here is why they matter. Health Canada's Special Access Program lets a doctor ask to use a drug that is not approved in Canada for a patient with a serious condition. Health Canada can say yes, but that only makes access possible. The company still decides whether to send the drug, and what it charges. Until the company answers, families cannot plan, and doctors cannot tell them what to expect.

Plans to apply in Canada, and the trials the company pointed to

On regulatory filings, the company said it is:

"in active dialogue with global regulators and are preparing submissions, but we're not providing specific filing timelines or details on the territory."

In plain English: the company is preparing to apply in other countries, but will not say when, or whether Canada is one of them. There is no Canadian filing date.

The company also pointed to clinical trials. We checked the public trial registry ourselves:

• MountainTAP-5 (NCT07492680, sponsored by Bristol Myers Squibb) lists Canadian sites in Vancouver and Toronto. As of November 5, those sites are not yet recruiting.
• A study sponsored by Tango Therapeutics (NCT06922591) is recruiting, but its registry record, last updated October 23, 2026, lists no Canadian sites. That study is not, today, a way for Canadians to get the drug in Canada.

Trial sites and recruitment change. If you are interested in a trial, ask your oncologist to check the current listing.

What happens next

We’ve sent out our response back to revolution medicines to again express the absolute sense of panic in the community at having to wait years for a drug, years when families have sometimes months.

We believe in constructive dialogue. But dialogue cannot become an excuse for indefinite delays, unanswered questions or inaction. Diplomacy with drug manufacturers is a luxury that patients with terminal illnesses simply do not have.

We will keep asking the questions above until Canadian families have answers. When we learn more, we will update this post, our Daraxonrasib explainer, and our community update log on r/CanPancreaticCancer.

If you are a patient or caregiver, here is what you can do now:

• Ask your oncologist whether a Special Access Program request is worth discussing for you.
• Ask whether you might be eligible for a clinical trial, in Canada or elsewhere.
• Ask about other treatment options available to you today.

This article is information, not medical advice. Please talk to your care team about any treatment decision.